Vilket är priset för Healios K.K. (4593)

Priset för Healios K.K. (4593) är $1.89

Vilket är marknadsvärdet för Healios K.K. (4593)

Marknadsvärdet för Healios K.K. (4593) är $254.55M

Healios K.K. (4593) Vinst

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

År	Vinst	Ändra
Inte tillräckligt med data för de angivna datumen.

År

Vinst

Ändra

Inte tillräckligt med data för de angivna datumen.

Företag	Vinst	Skillnad i vinst	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Företag

Vinst

Skillnad i vinst

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$5.27B

Argenx SE

ARGX.US

$1.95B

Moderna, Inc.

MRNA.US

$-3.09B

CSL Limited

CSL.AX

$-4.02B

Lonza Group AG

LONN.SW

Healios K.K.

4593

Kategori